Molecular structure of A 83-01, CAS Number: 909910-43-6
A 83-01 (CAS 909910-43-6)
See product citations (16)
Alternate Names:
A 83-01 is known as an ALK5, ALK4, and ALK7 inhibitor.
Application:
A 83-01 is an inhibitor of TGF-β type I receptor kinase (ALK5), activin type IB receptor (ALK4), and nodal type I receptor (ALK7).
CAS Number:
909910-43-6
Purity:
≥97%
Molecular Weight:
421.52
Molecular Formula:
C25H19N5S
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
Available in US only.
Available in US only.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
A 83-01 is a selective inhibitor of TGF-β type I receptor ALK5 kinase, type I activin/nodal receptor ALK4, and type I nodal receptor ALK7 (IC50 values are 12, 45, and 7.5 nM respectively). A 83-01 blocks phosphorylation of Smad2 and inhibits TGF-β-induced epithelial-to-mesenchymal transition. It only weakly inhibits ALK-1, -2, -3, -6 and MAPK activity. A 83-01 is more potent than SB 431542. Fibroblasts can be reprogrammed by A 83-01 into alternative lineages.
A 83-01 (CAS 909910-43-6) References
- The ALK-5 inhibitor A-83-01 inhibits Smad signaling and epithelial-to-mesenchymal transition by transforming growth factor-beta. | Tojo, M., et al. 2005. Cancer Sci. 96: 791-800. PMID: 16271073
- Attachment to laminin-111 facilitates transforming growth factor beta-induced expression of matrix metalloproteinase-3 in synovial fibroblasts. | Hoberg, M., et al. 2007. Ann Rheum Dis. 66: 446-51. PMID: 17124250
- Increase in tumour permeability following TGF-beta type I receptor-inhibitor treatment observed by dynamic contrast-enhanced MRI. | Minowa, T., et al. 2009. Br J Cancer. 101: 1884-90. PMID: 19888220
- Enhanced antitumor efficacy of folate-linked liposomal doxorubicin with TGF-β type I receptor inhibitor. | Taniguchi, Y., et al. 2010. Cancer Sci. 101: 2207-13. PMID: 20608940
- Topical application of ALK5 inhibitor A-83-01 reduces burn wound contraction in rats by suppressing myofibroblast population. | Sun, X., et al. 2014. Biosci Biotechnol Biochem. 78: 1805-12. PMID: 25351330
- Pharmacological inhibition of TGFβ receptor improves Nkx2.5 cardiomyoblast-mediated regeneration. | Chen, WP., et al. 2015. Cardiovasc Res. 105: 44-54. PMID: 25362681
- Optimized Approaches for Generation of Integration-free iPSCs from Human Urine-Derived Cells with Small Molecules and Autologous Feeder. | Li, D., et al. 2016. Stem Cell Reports. 6: 717-728. PMID: 27132887
- Small molecule-mediated reprogramming of human hepatocytes into bipotent progenitor cells. | Kim, Y., et al. 2019. J Hepatol. 70: 97-107. PMID: 30240598
- Tissue engineering approaches for treating pelvic organ prolapse using a novel source of stem/stromal cells and new materials. | Gargett, CE., et al. 2019. Curr Opin Urol. 29: 450-457. PMID: 31008783
- Regulatory expression of uncoupling protein 1 and its related genes by endogenous activity of the transforming growth factor-β family in bovine myogenic cells. | Abd Eldaim, MA., et al. 2021. Cell Biochem Funct. 39: 116-125. PMID: 33006416
- Chemical conversion of aged hepatocytes into bipotent liver progenitor cells. | Huang, Y., et al. 2021. Hepatol Res. 51: 323-335. PMID: 33378128
- A TGFβ Signaling Inhibitor, SB431542, Inhibits Reovirus-mediated Lysis of Human Hepatocellular Carcinoma Cells in a TGFβ-independent Manner. | Ishigami, I., et al. 2021. Anticancer Res. 41: 2431-2440. PMID: 33952468
- Successful induction of human chemically induced liver progenitors with small molecules from damaged liver. | Miyoshi, T., et al. 2022. J Gastroenterol. 57: 441-452. PMID: 35294680
- A Small-Molecule Cocktails-Based Strategy in Culture of Mesenchymal Stem Cells. | Feng, Y., et al. 2022. Front Bioeng Biotechnol. 10: 819148. PMID: 35360405
Inhibitor of:
β ig-h3, 4930558K02Rik, ACTR-IA, ACTR-IB, ACTR-IC, ACTR-IIA, ACTR-IIB, ADMP, AHNAK, ALK-1, Asporin, BC052484, BMP-3, BMP-8B, BMP2KL, BMPR-IB, BMPR-II, COL10A1, CRIM1, Cryptic, DAF-1, Dlx-5, dsg1α, EG668381, EMILIN-1, ER71, Evx-2, FGL1, FLRG, Fussel-18, GDF-1, GDF-11, GDF-3, GDF-5, GDF-7, GDF-9, GDF-9B, GDF5OS, gremlin-2, Inhibin β-A, Inhibin β-E, Keratocan, LOC645781, LOC646862, LRP4, LRRC32, LRRC70, LRRC72, MAGE-L2, MAWDBP1, Myocardin, Myotubularin (MTM, MTMR), Nodal, NOMO, NOMO1, NOMO2, NOMO3, NPN, Olfr478, Olfr479, Olfr583, PLAGL2, PMEPA1, Podocan, PTGF-β, RGMb, Ski, Sm B/B′, Smad1, Smad2, Smad3, Smad4, Smad5, Smad8, Smuc, Smurf2, SNIP1, Sox19, SPARCL1_Sc1, SSEA-3, TBCK, TBX22, Tenascin-N, TGF B3, TGF beta, TGF beta 1, TGF beta RI, TGFα, TGIF2LX2, TIAF-1, TIMAP, TMEM100, Trichohyalin, TSPYL1, Tyrosine Kinase, VIPL, VWC1, and ZBTB42.Activator of:
ACTR-IB, ACTR-IIA, ADAM33, ADMP, ALKBH5, BMP-5, BMP2, BMP2K, BPAG1n3, brachyury, brachyury 2, C030039L03Rik, C2orf15, C86695, C9orf156, Cactin, CCDC57, CD109, CDRT1, CNTD1, COL20A1, COL2A1, COL5A3, Cytokeratin 19, DAF-1, DAF-3, DAF-7, DAND5, Dapper3, dpp, DPPA2, EG546325, EG625424, EG625464, eotaxin-2, FGF-5, FHOD1, fibrillin-3, Fibroblast Marker, FOXN4, GDF-1, GDF-10, GDF-3, GRAF, GRHL1, Inhibin β-B, Integrin β6, Integrin β8, Keratin 34, LAP, Lefty, Lefty-1, Lefty-2, Lefty-A, Lefty-B, LIF, LMTK3, LRRC15, LRRC4B, LTBP-1, MAWDBP1, MMP-11, Nanog, Nkx-2.2, NOMO1, NURIM, Oct-3/4, PRL-2, PRPF4, PRRG1, PTD015, Ran BP-3, RBM42, Rpb3, SARA, SEMA5A, Six3, SK2, Smad, Smad6, Smad7, SnoN_SnoN2_SnoA, Sox-17, Sp5, SPRR1B, SSEA-4, STELLA, TBX2, TGF B-1, TGF B3, TGIF, TGIF2LX, TGIF2LY, TMTSP, TSC-22 D2, TSC-36, UBA5, Ubr3, USP17L4, USP17L7, USP17L8, UTP6, Vasorin, VEGF, VWC2, WFIKKN, WISP-2, Wnt-10b, ZNF512, ZNF512B, ZNF643, and ZSCAN4.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
A 83-01, 10 mg | sc-203791 | 10 mg | $202.00 | |||
| US: Only available in the US (Out of Stock: Availability September 26, 2025) | ||||||
A 83-01, 50 mg | sc-203791A | 50 mg | $811.00 | |||
| US: Only available in the US | ||||||